XML 13 R4.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses        
Research and development $ 3,923 $ 7,953 $ 7,516 $ 16,243
General and administrative 7,101 15,384 9,629 28,023
Total operating expenses 11,024 23,337 17,145 44,266
Other operating income 5 13 51 342
Loss from operations (11,019) (23,324) (17,094) (43,924)
Other income/(expense):        
Interest income 343 523 693 1,079
Interest expense (14) (12) (27) (25)
Research and development incentives 42 1,342 191 1,644
Other income 26 320 65 395
Total other income, net 397 2,173 922 3,093
Loss before income tax (10,622) (21,151) (16,172) (40,831)
Tax benefit 23 25 39 47
Net loss (10,599) (21,126) (16,133) (40,784)
Net loss attributable to noncontrolling interest 19 2 22 12
Net loss attributable to Barinthus Biotherapeutics plc shareholders $ (10,580) $ (21,124) $ (16,111) $ (40,772)
Weighted-average ordinary shares outstanding, basic (in shares) 40,848,893 40,343,521 40,848,893 40,304,584
Weighted-average ordinary shares outstanding, diluted (in shares) 40,848,893 40,343,521 40,848,893 40,304,584
Net loss per share attributable to ordinary shareholders, basic (in usd per share) $ (0.26) $ (0.52) $ (0.39) $ (1.01)
Net loss per share attributable to ordinary shareholders, diluted (in usd per share) $ (0.26) $ (0.52) $ (0.39) $ (1.01)
Net loss $ (10,599) $ (21,126) $ (16,133) $ (40,784)
Other comprehensive (loss)/gain – foreign currency translation adjustments 822 8,295 (2,014) 12,941
Comprehensive loss (9,777) (12,831) (18,147) (27,843)
Comprehensive loss/(gain) attributable to noncontrolling interest 18 (5) 23 2
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders $ (9,759) $ (12,836) $ (18,124) $ (27,841)